FY2025 · ended Dec 31, 2025 · Revenue $1.40B, +37.6% YoY · Filed Feb 17, 2026
Halozyme Therapeutics, Inc. (HALO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.4 billion and net income of $316.9 million. Free cash flow was $644.6 million. As of Jun 30, 2026 it held $163.1 million in cash and investments and $2.2 billion in total debt.
Revenue (TTM)
$1.66B
+41.2% vs year-ago TTM
Net income (TTM)
$413.60M
-25.8% vs year-ago TTM
Operating cash flow (TTM)
$818.60M
+49.4% vs year-ago TTM
Free cash flow (TTM)
$806.22M
+49.1% vs year-ago TTM
EPS (TTM)
$3.38
-22.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
118.02M
-4.2% vs prior year
Net cash
$-2.02B
as of Jun 30, 2026
Operating margin
35.9%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HALO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC (until Jul 3, 2019); GLOBAL YACHT SERVICES INC (until Mar 12, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M | $443.3M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B |
| Total liabilities | $2.5B | $1.7B | $1.6B | — | — |
| Stockholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M |
| Cash and investments | $133.8M | $115.8M | $118.4M | $362.8M | $740.9M |
| Total debt | $2.2B | $1.5B | $1.5B | $1.5B | $879.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 30, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Other events
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 1001 Halozyme Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.